An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

Condition:   Head and Neck Cancer
Interventions:   Biological: Nivolumab;   Drug: BMS-986205;   Biological: Cetuximab;   Drug: Cisplatin;   Drug: Carboplatin;   Drug: Fluorouracil
Sponsor:   Bristol-Myers Squibb
Not yet recruiting

http://ift.tt/2ltqOts